BioNTech Announces 2026 AGM; Proposes Supervisory Board Expansion and New Authorized Capital

BioNTech SE (BNTX) filed a Form 6-K on April 2, 2026, inviting shareholders to its Annual General Meeting (AGM) scheduled for May 15, 2026. A primary agenda item is a proposal to amend the Articles of Association to increase the Supervisory Board size from six to eight members. The company has nominated Dr. Susanne Schaffert and Prof. Dr. Iris Loew-Friedrich as the two new additional members, citing a need for expanded expertise in oncology, clinical development, and product commercialization. Additionally, the board seeks re-election for current members Helmut Jeggle, Prof. Dr. Anja Morawietz, and Prof. Dr. Rudolf Staudigl. Other significant proposals include the creation of a new "Authorized Capital 2026" amounting to EUR 129,513,743 (50% of current share capital) to replace the 2025 authorization, and the approval of a domination and profit and loss transfer agreement with its subsidiary, BioNTech Discovery GmbH. The meeting will also address the reauthorization of the Management Board to hold virtual AGMs for an additional two years. BioNTech reported a balance sheet profit of approximately EUR 6.9 billion for the 2025 financial year, which is proposed to be carried forward.